IP Verse

Rapid Dissolution Formulation Of Cinacalcet Hcl

Patent No. EP3395338 (titled "Rapid Dissolution Formulation Of Cinacalcet Hcl") was filed by Amgen on Sep 10, 2004. The application was issued on May 1, 2019.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BETAPHARM ARZNEIMITTELDec 9, 2020HAMM & WITTKOPP
AECHTERJan 31, 2020TER MEER STEINMEISTER & PARTNER
BIOGARANJan 31, 2020CASALONGA
HGFJan 31, 2020-
ACCORD HEALTHCAREJan 31, 2020TER MEER STEINMEISTER & PARTNER
GLENMARK PHARMACEUTICALS EUROPEJan 27, 2020SCHLICH
TEVA PHARMACEUTICALSJan 13, 2020ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3395338

AMGEN
Application Number
EP18175495A
Filing Date
Sep 10, 2004
Status
Revoked
Apr 29, 2022
Publication Date
May 1, 2019
External Links
Slate, Register , Google Patents